The present invention relates to method of treating a
gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HT3
receptor agonist activity or a pharmaceutically acceptable salt,
hydrate or solvate thereof; and a second amount of at least one
gastric acid suppressing agent (e.g., a
proton pump inhibitor, an H2
receptor antagonist or a pharmaceutically acceptable salt,
hydrate or solvate thereof; or an acid pump
antagonist or pharmaceutically acceptable salt,
hydrate or solvate thereof) wherein the first and second amounts together comprise a therapeutically effective amount. In particular, the method is for treating
GERD, including nocturnal
GERD. The invention further relates to a method of treating nocturnal
GERD comprising administering to a subject in need thereof a therapeutically effective amount of a compound having 5-HT3
receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The invention further relates to a method of increasing esophageal
motility in a subject in need thereof. The method of increasing esophageal
motility can be achieved by administration of a compound having 5-HT3
receptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The coadministration can also be used to increase esophageal
motility.